Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sincere CoTSE:7782 -0.87%78 Debt-to-EBITDA is 2.69 as of Dec. 2025, which is 22% below its 10-year median of 3.43. GuruFocus rates TSE:7782 with a GF Score™ of 78/100 and a GF Value™ of 円689.91 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 475 Medical Devices & Instruments companies, Sincere Co ranks worse than 72% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sincere Co's Debt-to-EBITDA or its related term are showing as below:
TSE:7782'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.6 Med: 3.43 Max: 13.69
Current: 3.32
During the past 12 years, the highest Debt-to-EBITDA Ratio of Sincere Co was 13.69. The lowest was 0.60. And the median was 3.43.
TSE:7782's Debt-to-EBITDA is ranked worse than 72% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs TSE:7782: 3.32
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sincere Co Debt-to-EBITDA Related Terms
Sincere Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sincere Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7782 vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Sincere Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sincere Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sincere Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sincere Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.
Sincere Co (TSE:7782) has a Debt-to-EBITDA of 2.69 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sincere Co. This is 22% below median its historical median of 3.43. Over the past decade, Sincere Co's Debt-to-EBITDA has ranged from 0.60 to 13.69. According to the industry distribution chart, Sincere Co ranks #342 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 72%.
Is Sincere Co's Debt-to-EBITDA too high?
Sincere Co's current Debt-to-EBITDA of 2.69 is 22% below median its 10-year median of 3.43. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 13.69. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.63. Sincere Co's value of 2.69 is 65% above this industry median. Based on the distribution chart, Sincere Co ranks #342 out of 475 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sincere Co has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sincere Co's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sincere Co ranks #342 out of 475 companies for Debt-to-EBITDA. This places Sincere Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Sincere Co's value of 2.69 is 65% above this benchmark. Historically, Sincere Co's own Debt-to-EBITDA has ranged from 0.60 to 13.69 over the past decade. While the company's 10-year median is 3.43 vs. the industry median of 1.63, Sincere Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sincere Co's current Debt-to-EBITDA of 2.69 is 65% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sincere Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sincere Co's current Debt-to-EBITDA is 2.69, which is 22% below median its own 10-year median of 3.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sincere Co stock overvalued right now?
Based on GuruFocus' analysis, Sincere Co (TSE:7782) is currently considered Significantly Undervalued. The stock's GF Value™ is 円689.91, compared to a current price of 円458.00 — trading 33.6% below its estimated fair value. The current Debt-to-EBITDA is 2.69, which is 22% below median its 10-year median of 3.43 and 65% above the Medical Devices & Instruments industry median of 1.63. Sincere Co's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sincere Co (TSE:7782), the current Debt-to-EBITDA is 2.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sincere Co (TSE:7782) Overvalued in 2026?
Based on GuruFocus' analysis, Sincere Co stock appears to be undervalued.
The current stock price of 円458.00 is trading 33.6% below its estimated GF Value™ of 円689.91.
GuruFocus considers Sincere Co to be Significantly Undervalued.
Key valuation signals for TSE:7782:
Debt-to-EBITDA: 2.69 (22% below median its 10-year median of 3.43)
GF Value™: 円689.91 vs. price of 円458.00 (33.6% below fair value)
Industry Position: 65% above the Medical Devices & Instruments median (#342 of 475)
No single metric tells the full story. See the TSE:7782 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sincere Co Ltd is a Japanese firm engaged in the manufacturing and sale of contact lens.As a company that manufactures and sells contact lenses, which are high-regulated medical devices, it place the highest priority on product safety and quality control, while working closely with company's customers to develop a variety-of-products and sell them at affordable prices to please as many customers as possible. The company opperates domestically as well as internationally.
78GF Score
Get the complete analysis for TSE:7782
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7782 has been successfully added to your 
